Emergent Biosolutions Stock Investor Sentiment

EBS Stock  USD 9.85  0.37  3.90%   
Slightly above 65% of all Emergent Biosolutions' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Emergent Biosolutions suggests that some traders are interested. Emergent Biosolutions' investing sentiment can be driven by a variety of factors including economic data, Emergent Biosolutions' earnings reports, geopolitical events, and overall market trends.

Panic Vs Confidence

65

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Emergent Biosolutions' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Emergent Biosolutions.

Emergent Historical Sentiment

Although Emergent Biosolutions' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Emergent, such as negative comments on social media and news outlets, may cause fear in the market and push Emergent Biosolutions' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Emergent.
  

Emergent Biosolutions Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Emergent Biosolutions can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Emergent Biosolutions Historical Investor Sentiment

Investor biases related to Emergent Biosolutions' public news can be used to forecast risks associated with an investment in Emergent. The trend in average sentiment can be used to explain how an investor holding Emergent can time the market purely based on public headlines and social activities around Emergent Biosolutions. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Emergent Biosolutions' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Emergent Biosolutions and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Emergent Biosolutions news discussions. The higher the estimate score, the more favorable the investor's outlook on Emergent Biosolutions.
over three months ago at seekingalpha.com         
Spain, Germany to donate mpox vaccine doses to Africa
seekingalpha News
over three months ago at news.google.com         
Mpox Vaccine Maker Bavarian Nordic Shares Soar Amid Concern Over Virus Outbreak - Forbes
Google News at Macroaxis
over three months ago at globenewswire.com         
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
Macroaxis News: globenewswire.com
over three months ago at globenewswire.com         
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
Emergent BioSolutions Speculative Buy Amid Potential Monkeypox Vaccine Approval - Seeking Alpha
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Why Emergent BioSolutions Stock Is Skyrocketing Today
Yahoo News
over three months ago at finance.yahoo.com         
Emergent BioSolutions Inc. Analysts Are Pretty Bullish On The Stock After Recent Results
Yahoo News
over three months ago at finance.yahoo.com         
Emergent Media and Pacifico Clara Expand Partnership with National Campaign
Yahoo News
over three months ago at finance.yahoo.com         
Emergent BioSolutions Second Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags
Yahoo News
over three months ago at insidermonkey.com         
Emergent BioSolutions Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at investing.com         
Earnings call Emergent BioSolutions raises 2024 guidance
Investing News at Macroaxis
over three months ago at seekingalpha.com         
Emergent Biosolutions Non-GAAP EPS of -2.32 misses by 1.35, revenue of 254.7M beats by 64.7M
seekingalpha News
over three months ago at investing.com         
Emergent Biosolutions earnings missed by 1.38, revenue topped estimates
Investing News at Macroaxis
over three months ago at finance.yahoo.com         
Emergent BioSolutions Q2 2024 Earnings Call Transcript
Yahoo News
over three months ago at globenewswire.com         
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Emergent Biosolutions that are available to investors today. That information is available publicly through Emergent media outlets and privately through word of mouth or via Emergent internal channels. However, regardless of the origin, that massive amount of Emergent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Emergent Biosolutions news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Emergent Biosolutions relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Emergent Biosolutions' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Emergent Biosolutions alpha.

Emergent Biosolutions Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Emergent BioSolutions Successfully Refinances Debt Further Strengthens Financial Profile
09/03/2024
2
Emergent BioSolutions Confirms Approximately 400 million in Orders in 2024 2025 to Support Smallpox and Mpox Preparedness Efforts
09/25/2024
3
Disposition of 4103 shares by Jennifer Fox of Emergent Biosolutions at 3.23 subject to Rule 16b-3
09/27/2024
4
Acquisition by Richard Lindahl of 15000 shares of Emergent Biosolutions subject to Rule 16b-3
10/15/2024
5
Acquisition by Ronald Richard of 33847 shares of Emergent Biosolutions subject to Rule 16b-3
10/18/2024
6
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
11/06/2024
7
Emergent BioSolutions stock target increased, keeps buy on strong Q3
11/07/2024
8
Emergent BioSolutions Inc. Q3 2024 Earnings Call Transcript
11/08/2024
9
Emergent Software Welcomes Industry Leader Marc Kermisch as Chief Technology Officer
11/11/2024
10
Emergent Metals Stock Price Up 15 percent Should You Buy
11/13/2024
11
Insider Sale Director Donald Degolyer Sells 25,000 Shares of Emergent BioSolutions Inc
11/15/2024
12
Insider Trading
11/18/2024
13
Emergents Vaccine Production Failure Contamination Scandal, Investor Backlash, and 40M Settlement
11/22/2024

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.